Microbot Medical (NASDAQ:MBOT), Inc. (NASDAQ: MBOT) is a clinical-stage medical device company focused on developing innovative micro-robotic technologies to transform minimally invasive procedures. The company’s platforms harness magnetic navigation, microfabrication and advanced control systems to deliver precision tools for interventional therapies. By combining robotics with catheter-based approaches, Microbot Medical strives to improve procedural efficiency and patient outcomes in a range of cardiovascular and peripheral vascular indications.
The company’s lead product candidates include the Hydra platform, designed to navigate and clear vascular obstructions in coronary and peripheral arteries. Hydra micro-robots are engineered to selectively remove plaque, thrombus and calcium build-up, offering a complementary approach to traditional balloon angioplasty and stenting. In preclinical studies, the platform has demonstrated the ability to access complex vessel anatomies and reduce the risk of downstream embolization, potentially enabling physicians to treat challenging lesions with greater confidence.
Founded in 2010, Microbot Medical is headquartered in New York with research and development operations in Israel. Over the past decade, the company has built a robust intellectual property portfolio, securing patents in key global markets. Strategic collaborations with leading academic medical centers and partnerships in Europe and Asia support ongoing clinical programs and regulatory filings. These efforts position Microbot Medical to advance toward first-in-human studies and future commercial adoption across developed and emerging healthcare markets.
Microbot Medical’s leadership team is led by Chairman and CEO Dr. Itai Yabe, who brings extensive experience in medical device innovation and corporate development. The executive suite includes Chief Medical Officer Dr. Eitan Ornoy and Chief Technology Officer Dr. Zvi Cohen, each contributing deep expertise in interventional cardiology and micro-robotic engineering. Together, they guide the company’s mission to deliver next-generation tools that address unmet needs in minimally invasive therapy.
